DB
WHWK

Dmitry Balyasny’s Whitehawk Therapeutics WHWK Stock Holding History

Dmitry Balyasny’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.32M Sell
288,117
-262,324
-48% -$1.09M ﹤0.01% 2053
2026
Q1 		$1.9M Buy
+550,441
New +$1.72M ﹤0.01% 1803
2022
Q2 		– Sell
-11,705
Closed -$199K – 3269
2022
Q1 		$199K Buy
+11,705
New +$224K ﹤0.01% 2027

Other funds holding WHWK

YF
Yu Fan $108M AUM 137.54% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $136M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dmitry Balyasny's WHWK Position: Q2 2026 in Review

Dmitry Balyasny reduced its Whitehawk Therapeutics (WHWK) stake by 48% in Q2 2026, selling an estimated $1.09M and leaving 288,117 shares worth $1.32M. The position accounts for ﹤0.01% of the portfolio, ranked #2053.

Dmitry Balyasny first reported a position in WHWK in Q1 2022 and has held it in 3 quarters since. The position peaked at $1.9M in Q1 2026. 78 funds tracked by Wall St. Rank hold WHWK as of Q2 2026.

  • Dmitry Balyasny held 288,117 shares of Whitehawk Therapeutics worth $1.32M as of Q2 2026.
  • Dmitry Balyasny sold 262,324 Whitehawk Therapeutics shares in Q2 2026, an estimated $1.09M.
  • Whitehawk Therapeutics made up ﹤0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #2053 holding.
  • Dmitry Balyasny first reported a position in Whitehawk Therapeutics in Q1 2022 and has held it in 3 quarters since.
  • Dmitry Balyasny's Whitehawk Therapeutics position peaked at $1.9M in Q1 2026.
  • 78 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.